The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
July 2021
in “Nature Communications”
TLDR The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
The document reports a study on the effects of the antiandrogen drug enzalutamide (ENZA) on the protein TMPRSS2, which is known to facilitate the entry of SARS-CoV-2 into cells. The study found that ENZA can downregulate TMPRSS2 levels in human lung cells and mouse lung tissue, leading to a significant decrease in SARS-CoV-2 cellular entry and infection. In vivo experiments with mice and in vitro experiments with A549 lung cells expressing the ACE2 receptor showed that ENZA and another antiandrogen, bicalutamide (BIC), significantly reduced viral entry and infection. The study supports the hypothesis that androgen receptor activation increases TMPRSS2 levels and suggests that antiandrogens could be a potential therapeutic option for COVID-19. The findings also highlight the potential for antiandrogen therapy to be well-tolerated in both men and women, proposing clinical trials to assess the efficacy of antiandrogens in treating COVID-19.
View this study on nature.com →
Cited in this study
research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
research Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research Cause of Androgenic Alopecia
Male pattern baldness may be caused by scalp pressure on hair follicles, which increases with age and leads to a cycle of hair loss. This process is not directly determined by genes.
research Visualising Androgen Receptor Activity in Male and Female Mice
Related
research Topical antiandrogens in the treatment of male-pattern baldness
Topical antiandrogens might be a good option for male-pattern baldness with fewer side effects, but more research is needed to confirm their safety and effectiveness.
research Pharmacology of antiandrogens
Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.